{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:31:41Z","timestamp":1791189101580,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,8,29]],"date-time":"2010-08-29T00:00:00Z","timestamp":1283040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00702-010-0472-x","type":"journal-article","created":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T22:39:30Z","timestamp":1282948770000},"page":"1279-1286","source":"Crossref","is-referenced-by-count":43,"title":["Levetiracetam for levodopa-induced dyskinesia in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1007","volume":"117","author":[{"given":"Martin","family":"Wolz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"L\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Strecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Schwanebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xina","family":"Gr\u00e4hlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,29]]},"reference":[{"issue":"8","key":"472_CR1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/mds.21500","volume":"22","author":"A Antonini","year":"2007","unstructured":"Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson\u2019s disease: 12-month treatment outcome. Mov Disord 22(8):1145\u20131149. doi: 10.1002\/mds.21500","journal-title":"Mov Disord"},{"issue":"6","key":"472_CR2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/mds.20385","volume":"20","author":"Y Awaad","year":"2005","unstructured":"Awaad Y, Michon AM, Minarik S (2005) Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 20(6):714\u2013718. doi: 10.1002\/mds.20385","journal-title":"Mov Disord"},{"issue":"1\u20133","key":"472_CR3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","volume":"485","author":"E Bezard","year":"2004","unstructured":"Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2004) Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 485(1\u20133):159\u2013164. doi: S0014299903027365","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"472_CR4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000029408","volume":"66","author":"KE Bloch","year":"1999","unstructured":"Bloch KE, Schoch OD, Zhang JN, Russi EW (1999) German version of the Epworth sleepiness scale. Respiration 66(5):440\u2013447","journal-title":"Respiration"},{"issue":"Pt 3","key":"472_CR5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/brain\/124.3.546","volume":"124","author":"T Boraud","year":"2001","unstructured":"Boraud T, Bezard E, Bioulac B, Gross CE (2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124(Pt 3):546\u2013557","journal-title":"Brain"},{"issue":"10 Suppl","key":"472_CR6","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","volume":"23","author":"TN Chase","year":"2000","unstructured":"Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23(10 Suppl):S86\u2013S91","journal-title":"Trends Neurosci"},{"issue":"5","key":"472_CR7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","volume":"64","author":"A Colzi","year":"1998","unstructured":"Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 64(5):573\u2013576","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"472_CR8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00002826-200305000-00008","volume":"26","author":"S Cristina","year":"2003","unstructured":"Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C (2003) High-dose ropinirole in advanced Parkinson\u2019s disease with severe dyskinesias. Clin Neuropharmacol 26(3):146\u2013150","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"472_CR9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C","volume":"14","author":"GL Defer","year":"1999","unstructured":"Defer GL, Widner H, Marie RM, Remy P, Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson\u2019s disease (capsit-pd). Mov Disord 14(4):572\u2013584","journal-title":"Mov Disord"},{"issue":"3","key":"472_CR10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62(3):381\u2013388","journal-title":"Neurology"},{"issue":"4","key":"472_CR11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","volume":"19","author":"AH Evans","year":"2004","unstructured":"Evans AH, Katzenschlager R, Paviour D, O\u2019Sullivan JD, Appel S, Lawrence AD, Lees AJ (2004) Punding in Parkinson\u2019s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19(4):397\u2013405. doi: 10.1002\/mds.20045","journal-title":"Mov Disord"},{"key":"472_CR12","doi-asserted-by":"crossref","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22(10):1379\u20131389. doi: 10.1002\/mds.21475 (quiz 1523)","DOI":"10.1002\/mds.21475"},{"key":"472_CR13","unstructured":"Fahn S, Elton RL, Committee UD (1987) The unified Parkinson\u2019s disease rating scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson\u2019s disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153\u2013163, 293\u2013304"},{"issue":"2","key":"472_CR14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 22(2):179\u2013186. doi: 10.1002\/mds.21226","journal-title":"Mov Disord"},{"issue":"5","key":"472_CR15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","volume":"16","author":"B Gomez-Mancilla","year":"1993","unstructured":"Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on l-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16(5):418\u2013427","journal-title":"Clin Neuropharmacol"},{"issue":"1\u20133","key":"472_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejphar.2008.10.048","volume":"601","author":"M Hamann","year":"2008","unstructured":"Hamann M, Sander SE, Richter A (2008) Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. Eur J Pharmacol 601(1\u20133):99\u2013102. doi: S0014-2999(08)01098-4","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"472_CR17","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1523\/JNEUROSCI.22-18-07850.2002","volume":"22","author":"G Heimer","year":"2002","unstructured":"Heimer G, Bar-Gad I, Goldberg JA, Bergman H (2002) Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism. J Neurosci 22(18):7850\u20137855. doi: 22\/18\/7850","journal-title":"J Neurosci"},{"issue":"3","key":"472_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"472_CR19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0896-6273(00)81046-6","volume":"24","author":"R Janz","year":"1999","unstructured":"Janz R, Goda Y, Geppert M, Missler M, Sudhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24(4):1003\u20131016. doi: S0896-6273(00)81046-6","journal-title":"Neuron"},{"issue":"2","key":"472_CR20","first-page":"295","volume":"75","author":"R Katzenschlager","year":"2004","unstructured":"Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ (2004) Low dose quetiapine for drug induced dyskinesias in Parkinson\u2019s disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 75(2):295\u2013297","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"472_CR21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"R Katzenschlager","year":"2005","unstructured":"Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: a prospective study using single-dose challenges. Mov Disord 20(2):151\u2013157. doi: 10.1002\/mds.20276","journal-title":"Mov Disord"},{"issue":"Suppl 4","key":"472_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1528-1157.2001.00003.x","volume":"42","author":"H Klitgaard","year":"2001","unstructured":"Klitgaard H (2001) Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 42(Suppl 4):13\u201318","journal-title":"Epilepsia"},{"issue":"3","key":"472_CR23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mds.20360","volume":"20","author":"N Kumar","year":"2005","unstructured":"Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE (2005) Levodopa-dyskinesia incidence by age of Parkinson\u2019s disease onset. Mov Disord 20(3):342\u2013344. doi: 10.1002\/mds.20360","journal-title":"Mov Disord"},{"issue":"1","key":"472_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1185\/030079903125002775","volume":"20","author":"A Kupsch","year":"2004","unstructured":"Kupsch A, Trottenberg T, Bremen D (2004) Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study. Curr Med Res Opin 20(1):115\u2013120. doi: 10.1185\/030079903125002775","journal-title":"Curr Med Res Opin"},{"issue":"26","key":"472_CR25","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101(26):9861\u20139866","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"472_CR26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/01.WNF.0000220814.48360.F4","volume":"29","author":"KE Lyons","year":"2006","unstructured":"Lyons KE, Pahwa R (2006) Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 29(3):148\u2013153. doi: 10.1097\/01.WNF.0000220814.48360.F4","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"472_CR27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.55.6.795","volume":"55","author":"AJ Manson","year":"2000","unstructured":"Manson AJ, Schrag A, Lees AJ (2000) Low-dose olanzapine for levodopa induced dyskinesias. Neurology 55(6):795\u2013799","journal-title":"Neurology"},{"issue":"4","key":"472_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2000.0689","volume":"42","author":"DG Margineanu","year":"2000","unstructured":"Margineanu DG, Klitgaard H (2000) Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42(4):281\u2013285. doi: 10.1006\/phrs.2000.0689","journal-title":"Pharmacol Res"},{"key":"472_CR29","first-page":"S35","volume":"6 Suppl 1","author":"PR May","year":"1983","unstructured":"May PR, Lee MA, Bacon RC (1983) Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches. Clin Neuropharmacol 6 Suppl 1:S35\u2013S51","journal-title":"Clin Neuropharmacol"},{"key":"472_CR30","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1353-8020(09)70004-5","volume":"15 Suppl 1","author":"T Nagatsua","year":"2009","unstructured":"Nagatsua T, Sawadab M (2009) l-Dopa therapy for Parkinson\u2019s disease: past, present, and future. Parkinsonism Relat Disord 15 Suppl 1:S3\u2013S8. doi: S1353-8020(09)70004-5","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"472_CR31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/00001756-200307010-00017","volume":"14","author":"I Niespodziany","year":"2003","unstructured":"Niespodziany I, Klitgaard H, Margineanu DG (2003) Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport 14(9):1273\u20131276. doi: 10.1097\/01.wnr.0000081866.45938.bf","journal-title":"Neuroreport"},{"issue":"1","key":"472_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0404.2005.00514.x","volume":"113","author":"P Odin","year":"2006","unstructured":"Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R, Shing M, Ludolph A, Schuler P (2006) Efficacy and safety of high-dose cabergoline in Parkinson\u2019s disease. Acta Neurol Scand 113(1):18\u201324","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"472_CR33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","volume":"85","author":"PN Patsalos","year":"2000","unstructured":"Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85(2):77\u201385. doi: S0163-7258(99)00052-2","journal-title":"Pharmacol Ther"},{"issue":"11","key":"472_CR34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN (2004) Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43(11):707\u2013724","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"472_CR35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","volume":"12","author":"M Pechevis","year":"2005","unstructured":"Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M (2005) Effects of dyskinesias in Parkinson\u2019s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 12(12):956\u2013963","journal-title":"Eur J Neurol"},{"issue":"4","key":"472_CR36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"WH Poewe","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245\u2013255","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"472_CR37","first-page":"101","volume":"9","author":"JR Pollard","year":"2008","unstructured":"Pollard JR (2008) Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs 9(1):101\u2013107","journal-title":"Curr Opin Investig Drugs"},{"issue":"6","key":"472_CR38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","volume":"4","author":"A Schrag","year":"2005","unstructured":"Schrag A (2005) Entacapone in the treatment of Parkinson\u2019s disease. Lancet Neurol 4(6):366\u2013370. doi: S1474-4422(05)70098-3","journal-title":"Lancet Neurol"},{"key":"472_CR39","doi-asserted-by":"crossref","unstructured":"Stocchi F (2009) The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson\u2019s disease. Parkinsonism Relat Disord 15(Suppl 3):S68\u2013S71. doi: S1353-8020(09)70784-9","DOI":"10.1016\/S1353-8020(09)70784-9"},{"key":"472_CR40","doi-asserted-by":"crossref","unstructured":"Stocchi F, Tagliati M, Olanow CW (2008) Treatment of levodopa-induced motor complications. Mov Disord 23(Suppl 3):S599\u2013S612. doi: 10.1002\/mds.22052","DOI":"10.1002\/mds.22052"},{"issue":"6","key":"472_CR41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.parkreldis.2005.03.005","volume":"11","author":"A Storch","year":"2005","unstructured":"Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J (2005) High-dose treatment with pergolide in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias. Parkinsonism Relat Disord 11(6):393\u2013398. doi: S1353-8020(05)00082-9","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"472_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.parkreldis.2004.11.003","volume":"11","author":"B Tousi","year":"2005","unstructured":"Tousi B, Subramanian T (2005) The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 11(5):333\u2013334. doi: S1353-8020(04)00196-8","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"472_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1212\/WNL.51.1.203","volume":"51","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN (1998a) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson\u2019s disease. Neurology 51(1):203\u2013206","journal-title":"Neurology"},{"issue":"5","key":"472_CR44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50(5):1323\u20131326","journal-title":"Neurology"},{"issue":"4 Suppl 1","key":"472_CR45","first-page":"S131","volume":"47","author":"JL Vitek","year":"2000","unstructured":"Vitek JL, Giroux M (2000) Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 47(4 Suppl 1):S131\u2013S140","journal-title":"Ann Neurol"},{"issue":"6","key":"472_CR46","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ana.20091","volume":"55","author":"J Volkmann","year":"2004","unstructured":"Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund HJ (2004) Long-term results of bilateral pallidal stimulation in Parkinson\u2019s disease. Ann Neurol 55(6):871\u2013875. doi: 10.1002\/ana.20091","journal-title":"Ann Neurol"},{"issue":"4","key":"472_CR47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","volume":"69","author":"SW Woods","year":"2008","unstructured":"Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C (2008) Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 69(4):546\u2013554. doi: ej07m03338","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"472_CR48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.20563","volume":"20","author":"TA Zesiewicz","year":"2005","unstructured":"Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA (2005) Open-label pilot study of levetiracetam (keppra) for the treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 20(9):1205\u20131209. doi: 10.1002\/mds.20563","journal-title":"Mov Disord"},{"issue":"11","key":"472_CR49","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/mds.21061","volume":"21","author":"TA Zesiewicz","year":"2006","unstructured":"Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J (2006) Open-label pilot study of levetiracetam (keppra) for the treatment of chorea in Huntington\u2019s disease. Mov Disord 21(11):1998\u20132001. doi: 10.1002\/mds.21061","journal-title":"Mov Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-010-0472-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0472-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:25:20Z","timestamp":1559089520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-010-0472-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,29]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s00702-010-0472-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,29]]}}}